Onco Actu du 15 juin 2016

	3.1.1 Tabac - e-cigs
Teens who vape e-cigs 'six times more likely to smoke cigarettes' [NHS Choices] This prospective cohort study found adolescents who used e-cigarettes were more likely to go on to use combustible tobacco products such as cigarettes, cigars and pipes than those who never used e-cigarettes. But the strength of these findings is limited by a number of factors.
	4. Dépistage, diagnostic et pronostic
Whole-body scans could track cancer in patients’ skeletons [The Institute of Cancer Research] Scientists at The Institute of Cancer Research, London, used an MRI technique called quantitative whole-body diffusion-weighted imaging (DWI) to measure skeletal tumours in nine patients with breast and prostate cancer.
Hitachi Developing Urine Test for Cancers of Breast and Colon [Bloomberg] Hitachi Ltd. said it is developing a simple urine test to screen for cancers of the breast and colon after trials with small numbers of patients helped it identify those suffering from the disease.
	4.10 Dép., diag. & prono. - Poumon
Family doctors don’t always screen smokers for lung cancer [Reuters] The researchers analyzed data from surveys completed by 101 family physicians in South Carolina in 2015. Most of the doctors were white, male and had graduated from medical school at least a decade ago.
	4.2 Dép., diag. & prono. - Génome
Should We Sequence the DNA of Every Cancer Patient? [MIT Technology Review] “We are sort of trickling toward precision medicine. Sequencing isn’t reimbursed because it’s not proven clinically, but it’s hard to prove without a big population of sequenced patients,” says Rhodes.
	5. Traitements
Autologous Stem Cell Transplantation Offers Safe and Effective—and Potentially Curative—Option for Patients with HIV-Associated Lymphoma [ASH] Multicenter, Phase II trial suggests autologous transplant should be standard of care for HIV patients with relapsed/treatment-resistant lymphoma.
Can you teach old drugs new tricks? [Nature News & Comment] Faced with skyrocketing costs for developing new drugs, researchers are looking at ways to repurpose older ones — and even some that failed in initial trials.
	5.12 Immunothérapies
Roche-backed researchers find a way to lure back immune system from cancer’s grasp [FierceBiotech] Writing in the journal Natural Cell Biology, researchers from École Polytechnique Federale de Lausanne (EPFL) say they have now found a way to reclaim the corrupted immune cells, turn them into signals for the immune system to attack the tumor, and even prevent cancer spreading.
Abstract Submission Deadline: June 16, 2016 [CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference] The deadline for abstract submission is 11:59 p.m. US Eastern Time on June 16, 2016. Please review the submission guidelines here.
	5.2 Pharma
Infinity Closes Research Ops as Blood Cancer Drug Comes Up Short [Xconomy] Duvelisib is a member of a more recent wave of PI3 kinase drugs, meant to be more targeted and safer than their predecessors. And despite the fact that the drug was well behind other rivals, like idelalisib, AbbVie was intrigued. AbbVie paid $275 million to grab rights to Infinity’s drug, and attached another $530 million in milestones to the deal.
Infinity’s Difficult History [In the Pipeline] Infinity stayed unbought, but as that first paragaph shows, it’s been a rough ride. I can’t think of a better illustration of how hard drug development is, and how it is no respecter of good ideas, hard work, and talent.
Infinity Reports Topline Results From DYNAMO™, A Phase 2 Monotherapy Study Of Investigational Molecule Duvelisib In Refractory Indolent Non-Hodgkin Lymphoma [Infinity Pharmaceuticals] Infinity is also undertaking a strategic restructuring that will close down its discovery research organization, impacting 46 members of the Infinity team, or 21 percent of the workforce.
Infinity Pharma back under a cloud after duvelisib disappoints in PhII [FierceBiotech] Almost all of Infinity’s eggs are in one basket for duvelisib. The biotech has 7 ongoing studies in the pipeline with 1 early-stage effort for IPI-549 in solid tumors.
	5.2.3 Pharma - économie
Global Cancer Nanomedicine Industry 2016 Market Research Report [ReportsnReports] The Cancer Nanomedicine market analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status.
Pharma’s secret weapon to keep drug prices high [STAT] Our patent system should reward only true inventions in science and medicine. In the face of public health epidemics and out-of-control drug pricing, we need a patent system that achieves a better balance between the interests of corporations and the public.
	6.6 Publications
Muddled meanings hamper efforts to fix reproducibility crisis [Nature News & Comment] Ultimately, each discipline may need to come to its own definition, says Lee Ellis, a surgical oncologist at the University of Texas MD Anderson Cancer Center in Houston.